BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 21154
Title: Neuroendocrine tumors resistant to mTOR inhibitors: A difficult conversion from biology to the clinic
Reviewer's code: 03413409
Reviewer's country: United States
Science editor: Fang-Fang Ji
Date sent for review: 2015-07-03 15:54
Date reviewed: 2015-07-05 20:07

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[Y] Accept
[Y] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In the present manuscript Author briefly discussed about the challenges associated with transition of pre-clinical findings into the clinical setting. Specifically, he reported the story of BEZ235 development, a multitargeted inhibitor which showed impressive pre-clinical activity but failed to show anti-tumor activity in the clinical setting. It also proved to be more toxic than other mTOR inhibitor like everolimus in this same setting. I don't have comments or concerns that may preclude further consideration for publication of this article.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 21154
Title: Neuroendocrine tumors resistant to mTOR inhibitors: A difficult conversion from biology to the clinic
Reviewer's code: 02793333
Reviewer's country: Switzerland
Science editor: Fang-Fang Ji
Date sent for review: 2015-07-03 15:54
Date reviewed: 2015-07-07 19:59

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The editorial entiteled "Neuroendocrine tumors resistant to mTOR inhibitors: a difficult conversion of biological aspects to clinical application" provides an important as well as up-to date statment relevant for NET and general Oncology.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 21154
Title: Neuroendocrine tumors resistant to mTOR inhibitors: A difficult conversion from biology to the clinic
Reviewer's code: 02520388
Reviewer's country: Germany
Science editor: Fang-Fang Ji
Date sent for review: 2015-07-03 15:54
Date reviewed: 2015-07-22 17:53

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[Y] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[Y] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The manuscript of Nicola Fazio deals with the clinically and scientifically very relevant topic of the huge differences between successful preclinical testing of novel anti-cancer compounds and their actual clinical effectiveness. Taking mTOR inhibition of neuroendocrine gastrointestinal tumors an example the author clearly describes the problem and failure of bringing an innovative compound such as BEZ235 from bench to bedside. The message of the paper is clear however, I missed some interpretation on the possible reasons and underlying mechanisms that account for the clinical failure of the multi-target inhibitor BEZ235 in neuroendocrine gastrointestinal tumors. The concluding remark that ….. "It is clear that transportomics and metabolomics are poorly known areas which can influence strictly the destiny of a drug." (page 2 last paragraph) is too general and needs interpretation and some more detailed explanation by taking actual work in the field into account. Generally, the text is well-written, but there are various grammatical and spelling mistakes, so the English needs a little brush-up.